AbbVie and Genmab disclosed that Epkinly (loncastuximab tesirine) did not extend overall survival in a Phase 3 trial for diffuse large B‑cell lymphoma (DLBCL). The companies reported topline results indicating the study did not meet its key efficacy endpoint, prompting an immediate reassessment of the drug’s label positioning and development pathway. The trial enrolled patients who had received at least one prior therapy; details on secondary endpoints, subgroup signals and safety were not provided in the initial notice. AbbVie and Genmab will need to decide whether to pursue additional analyses, potential niche indications, or regulatory discussions based on the full dataset. Investors and clinicians will watch subsequent data releases for guidance on whether any patient subpopulations derived benefit.